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levels were significantly higher at AE-COPD (130.25 pg/ml, 
95% CI 112.19–151.83) as compared to stable COPD (40.07 
pg/ml, 95% CI 37.13–43.96, p < 0.001). The association of
increased serum VIP with AE-COPD remained significant af-
ter propensity score matching (p < 0.001). Analysis of the 
Youden index indicated the optimal serum VIP cutoff value 
as 56.6 pg/ml. The probability of AE-COPD was very low if 
serum VIP was  ≤ 35 pg/ml (sensitivity >90%) and very high if 
serum VIP was  ≥ 88 pg/ml (specificity >90%). Serum VIP lev-
els presented a robust performance to diagnose AE-COPD 
(AUC 0.849, 95% CI 0.779–0.899).  Conclusions: Increased se-
rum VIP levels are associated with AE-COPD. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Chronic obstructive pulmonary disease (COPD) is a 
major global health problem  [1] and is the fourth leading 
cause of death in the world, claiming 3 million annual 
deaths worldwide  [2, 3] . Exacerbations are the most fre-
quent cause of hospitalization for COPD patients  [4] . 
They are commonly defined as ‘an event in the natural 
course of the disease characterized by a baseline change 
in the patient’s dyspnea, cough, and/or sputum that is be-
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 Abstract 
 Background: Vasoactive intestinal peptide (VIP) is the most 
abundant neuropeptide in the lung. VIP has been linked to 
pulmonary arterial hypertension and hypoxia.  Objectives: 
We aimed to assess circulating VIP levels at exacerbation and 
at stable chronic obstructive pulmonary disease (COPD) and 
to evaluate the diagnostic performance in a well-character-
ized cohort of COPD patients.  Methods: The nested cohort 
study included patients with Global Initiative for Chronic Ob-
structive Lung Disease stage II–IV. Patients were examined 
at stable state and at acute exacerbation of COPD (AE-COPD), 
and dedicated serum was collected at both conditions. Se-
rum VIP levels were determined by enzyme-linked immuno-
sorbent assay. Diagnostic accuracy was analyzed by receiver 
operating characteristic curve and area under the curve 
(AUC).  Results: Patients with acute exacerbation (n = 120) 
and stable COPD (n = 163) had similar characteristics at base-
line. Serum VIP levels did not correlate with oxygen satura-
tion at rest (p = 0.722) or at exercise (p = 0.168). Serum VIP 
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yond the normal day-to-day variations, is acute in onset, 
and may warrant a change in the regular medication in a 
patient with underlying COPD’  [5] . Today, there is no 
established gold standard that reliably allows diagnosis of 
exacerbation  [6, 7] .
 Although clear clinical criteria have been defined for 
COPD exacerbation, its initial diagnosis, especially in 
older, often multi-morbid patients in a busy general prac-
titioner’s office or emergency department tends to be 
challenging. The main reason is that, with the lack of a 
confirmatory test for the clinical impression, the diagno-
sis of COPD exacerbation usually requires the exclusion 
of alternative diagnoses such as congestive heart failure, 
pneumonia, bronchial cancer and pulmonary embolism, 
all commonly found in elderly patients with a history of 
smoking. This process is not only associated with consid-
erable financial and personal healthcare resources but 
also delays the timely treatment of exacerbation  [8–10] . 
The lack of a widely accepted, standard definition of ex-
acerbation also hampers the comparability of different 
studies, thus decreasing the external generalizability of 
COPD research  [4, 11] . Thus, practically, exacerbations 
are difficult to diagnose and therefore it is a worthwhile 
task to explore potential biomarkers that can be appoint-
ed for clinical use  [12] . Although some proteins have been 
suggested as potential markers of COPD exacerbation, up 
to now there is no single factor that can decisively iden-
tify it  [13, 14] .
 The most abundant neuropeptide in the lung is the va-
soactive intestinal peptide (VIP), which is a potent muscle 
relaxant and has therefore been suggested in the therapy 
of chronic inflammatory lung diseases, including COPD 
 [15, 16] . In experimental conditions, VIP has a positive 
inotropic and chronotropic effect. It relaxes pulmonary 
and coronary artery smooth muscles and in addition has 
shown anti-inflammatory effects in animal models  [16–
19] . In COPD rat models, VIP reduced cigarette smoke-
induced damage of alveolar cells and apoptosis  [20, 21] . 
In smoking COPD patients, increased expression of VIP 
was reported in the patients’ epithelium, while it was 
downregulated in their airway smooth muscle cell layer 
as compared to smokers without COPD  [22] . A similar 
increase in VIP was reported in arterial serum samples 
obtained from patients with COPD and pulmonary arte-
rial hypertension (PAH)  [23] .
 In human bronchial epithelial cells VIP supported 
wound healing through the cAMP response element-
binding protein (CREB)  [24] . Such beneficial effects of 
VIP on bronchial and alveolar epithelial cells were sup-
ported by animal models, where VIP protected against 
oxidative stress via a second transcription factor, the sig-
nal transducers and activators of transcription 3 (STAT3) 
 [25] . Furthermore, application of VIP prevented hyper-
oxia-induced pathologic lung function and tissue struc-
tural changes in rats  [26] . Together these results suggest 
that VIP is regulated and functions in a cell type-specific 
manner, with a beneficial effect on the regeneration and 
function of bronchial epithelium. Thus, circulating VIP 
levels may indicate active inflammation and wound re-
pair in the bronchus and may be useful as an early bio-
marker of exacerbation in COPD. Recently, attention has 
been directed towards the therapeutic potential of VIP for 
the treatment of COPD, as it acts as a neurotransmitter 
and has anti-inflammatory properties  [27] .
 In this study we investigated serum VIP levels in ded-
icated samples at AE-COPD and stable state in a well-
characterized cohort of COPD patients. The accuracy of 
serum VIP for the diagnosis of exacerbation in COPD 
was also evaluated.
 Subjects and Methods 
 Study Design and Patients 
 The ‘Predicting Outcome Using Systemic Markers in Severe 
Exacerbations of Chronic Obstructive Pulmonary Disease’ 
(PROMISE-COPD) was a multicenter study, from November 
2008 to October 2011, done to evaluate the potential variables as-
sociated with poor outcomes in moderate to very severe COPD 
patients. COPD was defined as post-bronchodilator FEV 1 /FVC 
<70% and FEV 1 <80% predicted, i.e. Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) grade II–IV airway obstruction 
 [28] .
 The study was designed to be inclusive, exploratory and hy-
pothesis-generating. It was specifically drafted to identify predic-
tors of outcome using systemic markers in COPD. In this analysis, 
a nested, predefined cohort of 241 patients (at stable state and fol-
lowed up longitudinally) from Basel, Switzerland was included. It 
was performed according to the PRoBE (prospective specimen col-
lection, retrospective blinded evaluation) standards  [29] . The ex-
pected follow-up period was 5 years. All enrolled patients had an 
initial baseline examination at stable state and were followed up for 
at least 2 years in scheduled half-yearly visits. Blood samples were 
collected at both stable state and at exacerbation for the purpose of 
this analysis. When necessary, patients made outpatient visits or 
were hospitalized for treatment of AE-COPD, and follow-up visits 
were performed 4 weeks after the onset of exacerbation. The inclu-
sion criteria were: (1) at baseline: clinically stable, moderate to very 
severe COPD (stages II–IV, according to the GOLD classifica-
tion)  [1] based on anamnesis, physical examination and spirom-
etry  ≥ 4 weeks after the latest exacerbation; (2) age  ≥ 40 years;
(3) smoking history  ≥ 10 pack-years. The exclusion criteria were: 
(1) main respiratory disorder such as asthma, bronchiectasis or 
pulmonary fibrosis; (2) other fatal disease; (3) immunosuppres-
sion, including AIDS, organ transplantation or current chronic 
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steroids (>20 mg prednisolone per day); (4) neuromuscular or 
musculoskeletal disorder preventing walking.
 Throughout the study period, patients were treated as clini-
cally warranted, without restriction. They were monitored for re-
current moderate (requiring treatment with systematic corticoste-
roids, antibiotics or both) and severe AE-COPD (requiring hospi-
talization or a visit to the emergency department).
 The PROMISE-COPD, an investigator-initiated and -driven 
study, complying with the Helsinki Declaration and Good Clinical 
Practice Guidelines, was approved by the participating centers’ 
ethics committees (EKBB 295/07) and was registered at www.con-
trolled-trials.com (identifier ISRCTN99586989). All patients pro-
vided prior written consent for the study assessments.
 Baseline and Scheduled Visit Assessments 
 For all patients, we performed a physical examination, regis-
tered vital signs and obtained a detailed medical history, which in-
cluded their demography, smoking status, disease duration, cur-
rent treatment as well as number and severity of exacerbations in 
the previous year. From the data the age-adjusted Charlson Comor-
bidity Index score was calculated. We also obtained plasma samples 
for measurement of biomarkers and spontaneous sputum samples 
for quantitative bacterial culture. Physical examinations, spirome-
try and 6-minute walking tests were performed by qualified person-
nel according to the guidelines of the American Thoracic Society 
 [30] . Each patient completed the Modified Medical Research 
Council (MMRC) scale, the St. George’s Respiratory Question-
naire, COPD version and the Short Form 36 health-related, quality 
of life questionnaire. All examinations took place at each scheduled 
visit (semi-annually), except for the 6-minute walking tests.
 Presence of PAH was defined as systolic pulmonary pressure 
>35 mm Hg within 6 months of baseline and determined by echo-
cardiography.
 Outcome Assessment 
 At the 2-year follow-up, the vital status of each patient was con-
firmed and, if required, by relatives, family physicians, medical in-
surance companies, by checking medical records, hospital databases 
or public registries. These methods were also used to determine the 
dates and causes of death, if any. Death dates that were undetermin-
able were imputed to the halfway point between the last study visit 
and the date when the investigator learned about the death.
 Unscheduled Visits during Exacerbation 
 Exacerbation was defined as an acute change from baseline in 
one or more of dyspnea, cough and sputum, beyond normal day-
to-day variation and possibly warranting change in medication. 
Visits derived from exacerbation were classified as unscheduled 
visits. Severe exacerbation was defined as the patients having to be 
admitted to the hospital for treatment  [1] . Spontaneously expecto-
rated sputum samples were obtained and examined using standard 
techniques  [31] . Sputum microbiology was performed and good 
sputum quality was defined as <25 epithelial cells in 100× augmen-
tation. Patients were asked to report to or call the study center on 
worsening of respiratory symptoms. Chest radiography and elec-
trocardiography were performed at the discretion of the attending 
physician to exclude other respiratory and cardiac pathologies. 
71.6% (n = 86) of the patients had either a chest X-ray or CT scan 
performed. Electrocardiography was obtained in 13.3% (n = 16) of 
the patients.
 AE-COPD patients were categorized as type 1 (severe with dys-
pnea, sputum volume and sputum purulence), type 2 (moderate 
with any two of the above three main symptoms) and type 3 (mild 
with any one of the three main symptoms) based on Anthonisen’s 
classification of COPD exacerbation  [32] .
 VIP Enzyme-Linked Immunosorbent Assay 
 Blood samples for VIP measurement were collected on the 
scheduled (stable state of the disease) and unscheduled visits (AE-
COPD) of each patient into Vacutainer tubes through an indwell-
ing venous catheter. Serum was collected after centrifugation 
(3,000  g , 10–15 min, 4   °   C) and was immediately fast-frozen at 
–80  °  C for analysis. In addition, serum samples were drawn at the 
same visit and processed routinely.
 VIP enzyme-linked immunosorbent assay (VIP-ELISA) was 
performed with fast-frozen samples (n = 241) and routinely pro-
cessed serum samples (n = 20) according to the manufacturer’s in-
structions, with a detection range of 15.6–1,000 pg/ml and <3.9 pg/
ml sensitivity (Cusabio Biotech Co. Ltd., China). VIP-ELISA was 
also performed in serum samples obtained from healthy blood do-
nors (n = 30) and used as the reference value of serum VIP ranging 
from 20 to 22 pg/ml. All serum samples were assayed in duplicate, 
in a single run by personnel unaware of the patients’ clinical data.
 Statistics 
 Continuous variables are expressed as mean ± SD or median 
(interquartile range: 25th to 75th percentile) and discrete variables 
as percentage. Baseline characteristics were compared between pa-
tients with stable COPD and AE-COPD by Mann-Whitney U test 
or Student’s t test, as appropriate. All tests were two-tailed and p 
values <0.001/0.05 were defined as significant. All statistical analy-
ses were performed using SPSS (version 22.0 for Macintosh, IBM, 
Switzerland). The longitudinal change in the VIP level in paired 
samples (n = 30 and n = 24; stable and exacerbated COPD) was 
analyzed by a non-parametric, paired test (Wilcoxon test). The 
MedCalc software (version 15.2, Belgium) was used for calculating 
sensitivity, specificity, negative likelihood ratio and positive likeli-
hood ratio. The diagnostic accuracy of the serum VIP level for AE-
COPD was evaluated using receiver operating characteristic 
(ROC) analysis and area under the curve (AUC).
 Propensity Score Matching 
 In order to compare study groups the data were adjusted for 
additional covariates by propensity score adjustment. Adjusted 
variables included all lung function as well as clinical and demo-
graphic characteristics as depicted in  table 1 .
 The difference in serum VIP between the study groups (stable 
group, mild to moderate AE-COPD group and severe COPD 
group) was calculated using a regression model with the propen-
sity score as an additional covariate  [33] .
 Results 
 Patient Characteristics 
 The study design according to the Strengthening the 
Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines and patient disposition is summa-
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 Table 1.  Characteristics of 241 patients included in the predefined VIP nested cohort at baseline (stable state)
Characteristics VIP nested
cohort
(n = 241)
Stable
(n = 163a)
 AE-COPD (n = 120) p
valuec
all 
(n = 120)
mild-moderate
(n = 65b)
severe
(n = 60)
Age, years 66.05 ± 11.6 65.75 ± 11.0 67.07 ± 11.8 66.14 ± 13.6 68.32 ± 9.1 0.339
Male gender 164 (68.0) 117 (71.8) 78 (65.0) 43 (66.2) 39 (65.0) 0.124
BMI, kg/m2 26.17 ± 5.9 26.37 ± 6.4 25.73 ± 4.8 26.39 ± 4.7 25.15 ± 5.1 0.343
Weight, kg 74.85 ± 18.4 75.78 ± 19.9 72.92 ± 16.2 74.71 ± 16.1 71.15 ± 17.2 0.199
Height, cm 168.87 ± 8.2 169.26 ± 8.1 168.02 ± 8.3 167.94 ± 8.2 168.24 ± 8.4 0.210
White 240 (99.6) 163 (100) 119 (99.2) 64 (98.5) 60 (100) 0.319
COPD history
Current smoker 70 (29.0) 51 (31.3) 28 (23.3) 15 (23.1) 14 (23.3) 0.173
Pack-years 51.2 ± 27.7 53.20 ± 27.5 50.82 ± 30.0 45.31 ± 27.5 56.55 ± 30.5 0.493
Duration of COPD symptoms, months 101.33 ± 82.1 91.46 ± 71.1 117.37 ± 92.3 137.87 ± 111.2 103.45 ± 73.4 0.008
Time elapsed since diagnosis, months 81.1 ± 73.2 76.58 ± 71.4 92.71 ± 75.8 108.67 ± 89.5 80.78 ± 57.0 0.069
MMRC dyspnea scale 1 [0 – 4] 1 [0 – 4] 2 [0 – 4] 2 [0 – 4] 2 [0 – 4] 0.066
BODE index 3 [0 – 9] 3 [0 – 9] 3 [0 – 8] 2 [0 – 8] 3 [0 – 8] 0.500
6-Minute walking test, m 378.0 ± 102.5 371.4 ± 106.5 377.83 ± 97.8 417.53 ± 81.3 336.85 ± 95.2 0.616
Borg score 3 [0 – 10] 3 [0 – 10] 4 [0 – 10] 4 [1 – 10] 4 [0 – 9] <0.001
SaO2 at rest, % 94.27 ± 2.8 94.15 ± 2.7 94.28 ± 3.01 94.9 ± 2.32 93.74 ± 3.4 0.722
Lowest SaO2 at exercise, % 88.54 ± 6.08 87.57 ± 6.1 88.63 ± 6.2 90.71 ± 5.5 86.46 ± 6.1 0.168
Heart rate at rest, bpm 81.34 ± 14.0 81.11 ± 14.1 82.09 ± 13.9 81.22 ± 12.9 83.44 ± 14.7 0.575
Highest heart rate at rest, bpm 107.94 ± 16.9 109.62 ± 15.8 106.78 ± 18.3 104.59 ± 17.5 109.25 ± 18.6 0.178
Comorbidities
Arterial hypertension 126 (52.3) 91 (55.8) 59 (49.2) 30 (46.2) 32 (53.3) 0.190
Coronary artery disease 61 (25.3) 50 (30.7) 22 (18.3) 11 (16.9) 12 (20.0) 0.016
Congestive heart failure 48 (19.9) 42 (25.8) 17 (14.2) 9 (13.8) 9 (15.0) 0.014
Diabetes mellitus 27 (11.2) 21 (12.5) 15 (12.5) 9 (13.84) 8 (13.3) 0.852
Dementia 4 (1.7) 3 (1.8) 2 (1.7) 1 (1.5) 1 (1.7) 0.913
Depression 35 (14.5) 25 (15.3) 17 (14.2) 8 (12.3) 10 (16.7) 0.785
Malignancy 11 (4.6) 8 (4.9) 4 (3.3) – 3 (5.0) 0.518
Myocardial infarction 21 (8.7) 15 (9.2) 10 (8.3) 7 (10.8) 3 (5.0) 0.800
Pulmonary hypertension 33 (13.7) 27 (16.6) 18 (15.0) 5 (7.7) 13 (21.7) 0.723
Renal failure 21 (8.7) 18 (11) 8 (6.6) 3 (1.5) 5 (8.3) 0.257
Age-adjusted Charlson Comorbidity Index score 4.0 ± 1.7 4.0 ± 1.8 4.0 ± 1.5 4.0 ± 1.5 4.0 ± 1.6 0.560
St. George’s Respiratory Questionnaire
Symptoms score 53.5 ± 22.38 52.14 ± 22.50 57.42 ± 21.73 55.56 ± 21.19 57.73 ± 22.49 0.055
Activity score 57.96 ± 22.62 55.87 ± 21.87 62.82 ± 23.27 59.31 ± 24.11 65.93 ± 21.08 0.013
Impact score 32.38 ± 18.21 29.66 ± 17.99 36.82 ± 18.05 34.62 ± 15.25 37.97 ± 20.59 0.002
Total score 43.52 ± 17.82 41.29 ± 17.32 48.09 ± 18.18 45.37 ± 16.76 49.82 ± 19.24 0.003
Short Form 36
Physical function 51.65 ± 25.6 54.9 ± 25.5 46.09 ± 25.1 47.77 ± 25.6 45.78 ± 24.4 0.005
Role physical 41.22 ± 41.9 41.06 ± 41.8 37.39 ± 42.1 44.14 ± 44.7 33.93 ± 40.2 0.482
Role emotional 64.42 ± 44.5 66.67 ± 44.5 60.23 ± 44.7 59.79 ± 44.8 64.29 ± 44.4 0.247
Social functioning 68.5 ± 27.8 71.42 ± 26.4 64.19 ± 29.3 66.99 ± 30.4 62.71 ± 28.6 0.035
Mental health 65.09 ± 17.9 67.05 ± 17.0 63.16 ± 19.1 64.53 ± 20.3 62.07 ± 17.2 0.081
Body pain 75.14 ± 28.3 76.88 ± 27.5 71.53 ± 29.4 74.81 ± 29.6 68.41 ± 28.2 0.142
Vitality 47.77 ± 18.8 47.15 ± 18.0 46.78 ± 19.9 48.89 ± 19.5 45.47 ± 19.9 0.874
General health 47.85 ± 22.3 50.04 ± 22.6 43.10 ± 21.4 40.53 ± 22.0 46.32 ± 20.1 0.020
COPD assessment 
GOLD graded
II 112 (46.5) 72 (44.17) 53 (44.16) 34 (52.3) 20 (33.3) 0.488
III 96 (39.8) 62 (38.0) 53 (44.2) 27 (41.5) 30 (50.0)
IV 31 (12.9) 29 (17.8) 14 (11.7) 4 (6.2) 10 (16.7)
Lung function parameters
FVC, post-brd, % predicted 81.59 ± 19.2 77.36 ± 17.7 84.45 ± 20.7 86.84 ± 20.8 81.6 ± 20.0 0.003
FEV1, post-brd, %predicted 48.88 ± 16.2 47.91 ± 16.8 47.66 ± 15.7 50.49 ± 14.6 44.48 ± 15.9 0.903
FEV1/FVC post-brd, % 45.95 ± 14.2 47.04 ± 14.5 43.5 ± 12.8 45.9 ± 14.5 41.12 ± 10.6 0.040
(For footnote see next page.)
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rized in  figure 1 . In total, 241 patients with GOLD grade 
II–IV were included in the predefined VIP nested cohort. 
Out of the 241, serum VIP levels were analyzed in 163 
patients at stable state and in 120 patients with AE-COPD.
 Table 1 depicts the demographic characteristics of sta-
ble patients in whom VIP level were assessed at both sta-
ble state and at exacerbation. The comparison of stable 
COPD versus AE-COPD showed similar demographics 
at baseline.
 At baseline, the Borg score was significantly higher in 
patients developing AE-COPD (p < 0.001). In contrast, 
the forced vital capacity (FVC post-bronchodilator per-
centage predicted) was significantly lower in stable COPD 
versus AE-COPD patients (p = 0.003). Additionally, sig-
nificant differences were found at baseline between pa-
tients who remained stable and those who had exacerba-
tion during follow-up, for the activity score (p = 0.013), 
the impact score (p = 0.002), the total score (p = 0.003) 
and physical function (p = 0.005).
 Serum VIP Level in Stable and AE-COPD Patients 
 Serum VIP levels were significantly higher in AE-
COPD patients (median 130.25 pg/ml, 95% CI 112.19–
151.83) as compared to patients with stable COPD (me-
dian 40.07 pg/ml, 95% CI 37.13–43.96, p < 0.001). Impor-
tantly, the association of increased serum VIP with 
AE-COPD remained significant after propensity score 
matching (p < 0.001). Serum VIP levels were similar in 
mild to moderate and severe AE-COPD (p = 0.805) 
( fig. 2 ). Circulating serum VIP levels did not differ among 
Anthonisen’s exacerbation types (type 1, n = 55; type 2,
n = 25; type 3, n = 35; p = 0.740).
 The longitudinal change in circulating VIP levels at 
stable state and at exacerbation for 30 patients is depicted 
in  figure 3 a and indicates a significant increase at exac-
erbation (p < 0.001). Out of these 30 patients, 6 had very 
high serum VIP at exacerbation. Upon exclusion of these 
extreme values, serum VIP level still remained signifi-
cantly higher at exacerbation than at stable state (p < 
0.001) ( fig. 3 b).
 Association of Serum VIP Level and Clinical 
Characteristics at Stable State 
 At stable state, there was no significant difference of 
serum VIP comparing patients with comorbidities to 
those without history of myocardial infarction (p = 0.936), 
arterial hypertension (p = 0.731), coronary artery disease 
(p = 0.831), diabetes mellitus (p = 0.438), malignant solid 
 Continuous data are shown as mean ± SD or median [interquartile range] and categorical variables as n (%). BODE = Body mass index, airflow 
obstruction, dyspnea and exercise capacity; bpm = beats/min; brd = bronchodilator; SaO2 = peripheral oxygen saturation. a 42 COPD patients were at stable 
state and had acute exacerbation. b 5 patients had both mild to moderate and severe AE-COPD. c Stable COPD versus AE-COPD (all). d GOLD grades are 
based on FEV1% predicted: II = ≥50% and <80%; III = ≥30% and <50%; IV = <30%. There were no patients with GOLD grade I COPD due to the study 
inclusion criteria.
(Footnote to table 1.)
Enrolled in PROMISE-COPD: 638 patients with COPD (GOLD stages II–IV)
241 patients included in the predefined VIP nested cohort
163* patients at stable state
COPD
120 patients with
AE-COPD
65** patients with
mild-moderate exacerbation
60 patients with severe
AE-COPD
 Fig. 1. STROBE flow chart of the patient 
cohort selection criteria.  * 42 COPD pa-
tients were at stable state and had acute ex-
acerbation.  * * 5 patients had both mild to 
moderate and severe AE-COPD. 
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tumor (p = 0.899), PAH (p = 0.361) and depression (p = 
0.172). Conversely, VIP levels were significantly higher in 
patients with congestive heart failure (p = 0.035) and renal 
diseases (p = 0.036) as compared to those without these 
comorbidities. There was no association between the se-
rum VIP and post-bronchodilator FEV1% predicted (p = 
0.250). Serum VIP levels did not correlate with blood oxy-
gen saturation at rest (p = 0.722) or at exercise (p = 0.168).
 Association of Serum VIP Level and Clinical 
Characteristics at Exacerbation 
 The clinical characteristics of patients at exacerbation 
are depicted in  table  2 . Cultures from sputum yielded 
pathogenic bacteria in 15 patients (12.5%).  Streptococcus 
pneumoniae accounted for 3.3%,  Klebsiella pneumoniae 
for 1.7%,  Chlamydia pneumoniae for 1.6%,  Haemophilus 
influenzae for 2.5% and  Staphylococcus aureus for 1.7%. 
Serum VIP did not correlate significantly with oxygen 
saturation at rest at exacerbation (p = 0.322). Serum VIP 
levels showed no correlation to C-reactive protein (p = 
0.451). At exacerbation, we observed no association of 
serum VIP with relevant comorbidities (p = not signifi-
cant for all). However, AE-COPD patients with coronary 
artery disease had a significant increase in serum VIP
(p = 0.020). There was no association between circulating 
VIP levels and the duration of exacerbation (p = 0.260), 
dyspnea at exacerbation as assessed by the MMRC scale 
(p = 0.092) or the presence of fever (n = 20, p = 0.177). 
We found no significant association of VIP to leucocyte 
count (p = 0.713) and FEV1% predicted (p = 0.805). VIP 
was neither associated to PaO 2 (p = 0.286) nor PaCO 2 
(p = 0.596). VIP levels were similar in those treated with 
and without oral steroids (n = 83, p = 0.530) and antibiot-
ics (n = 74, p = 0.377).
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 Fig. 2. Serum VIP in patients with stable COPD versus AE-COPD 
(data are expressed in box plots, vertical lines represent the 5th
and the 95th percentiles). p values were calculated by Mann-Whit-
ney U test. 
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when extreme VIP values were excluded (n = 24). p value was cal-
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 Table 2. Clinical characteristics of 120 patients at AE-COPD
Characteristics
Symptoms of exacerbation 
Increased dyspnea 111 (92.5)
Increased sputum volume 74 (61.6)
Increased sputum purulence 67 (55.8)
Sputum volume
No sputum 21 (17.5)
Large amount (>1 soup spoon) 14 (11.6)
Moderate amount (1 soup spoon) 43 (35.8)
Small amount (1 tea spoon) 41 (34.1)
Sputum color
No sputum 25 (21.0)
Purulent-green 14 (11.7)
Purulent-yellow 43 (35.8)
Transparent 7 (5.8)
White 30 (25.0)
Duration of symptoms prior to visit 5 [0 – 30]
Chest X-ray and/or chest CT scan 86 (71.6)
Sputum microbiology 
Sputum collected 49 (40.8)
Good sputum quality 41 (34.1)
Culture performed 42 (35.0)
Potentially pathogenic microorganisms 15 (12.5)
Treatment of exacerbation
Combination of inhaled beta2-agonists and anticholinergics 40 (33.3)
Inhaled steroids 30 (25.0)
Oral, intramuscular or intravenous glucocorticosteroids 82 (68.3)
Oral or intravenous antibiotics 73 (60.8)
Oral or intravenous methylxanthines 12 (10.0)
Oxygen 39 (32.5)
New prescription or increased dosage of diuretic therapy 6 (5.0)
Severity of exacerbation
Patients requiring hospitalization 15 (12.5)
Length of hospital stay, days 10 [1 – 28]
Noninvasive mechanical ventilation 3 (2.5)
Invasive mechanical ventilation 1 (0.8)
Indications for hospital admission for COPD exacerbation
Marked increase in intensity of symptoms, such as sudden development of resting dyspnea 34 (28.3)
Severe underlying COPD 37 (30.8)
Onset of new physical signs (e.g. cyanosis, peripheral edema) 9 (7.5)
Failure of exacerbation to respond to initial medical management 16 (13.3)
Significant comorbidities 20 (16.6)
Frequent exacerbations 20 (16.6)
Newly occurring arrhythmias 1 (0.83)
Diagnostic uncertainty 3 (2.5)
Older age 21 (17.5)
Insufficient home support 10 (8.3)
Indication for potential ICU admission of patients hospitalized with exacerbation of COPD
Severe dyspnea responding inadequately to initial emergency therapy 2 (1.6)
Changes in mental status (confusion, lethargy, coma) 3 (2.5)
Persistent or worsening hypoxemia (PaO2 8.0 kPa, 60 mm Hg), and/or severe/worsening respiratory
acidosis (pH <7.25) despite supplemental oxygen and noninvasive ventilation
2 (1.6)
Hemodynamic instability – need for vasopressors 1 (0.83)
Continuous data are shown as median [interquartile range] and categorical variables as n (%).
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 Effect of Serum Processing on VIP Level 
 Comparing serum VIP levels in fast-frozen serum 
samples directly and after repeated thawing from identi-
cal stable state COPD patients (n = 20), we observed that 
only fast-frozen serum contained measurable amounts of 
VIP, while repeated thawing (1×) degraded VIP to unde-
tectable levels ( fig. 4 ).
 Diagnostic Performance of Serum VIP 
 Using the AUC and 95% CI of ROC analysis, increased 
serum VIP levels in AE-COPD proved to have a robust 
performance (AUC 0.849, 95% CI 0.779–0.899) to diag-
nose exacerbation ( fig. 5 a). According to the Youden in-
dex, the optimal cutoff value for serum VIP in AE-COPD 
was 56.6 pg/ml. The probability of exacerbation was very 
low when serum VIP was  ≤ 35 pg/ml (sensitivity >90%) 
and very high when serum VIP was  ≥ 88 pg/ml (specific-
ity >90%). We did not find a difference in the diagnostic 
performance in Anthonisen type 1, type 2 and type 3 pa-
tients.
 Diagnostic performance of serum VIP improved 
(AUC 0.908, 95% CI 0.838–0.978; AUC 0.910, 95% CI 
0.830–0.989) in patients having paired stable and exacer-
bation VIP levels (n = 30) ( fig. 5 b) and also when extreme 
VIP values were excluded (n = 24) ( fig. 5 c).
 Upon dichotomizing by lung function, the perfor-
mance of serum VIP tended to be better in GOLD grade 
II (sensitivity = 84.6%, specificity = 76.0%, negative likeli-
hood ratio = 0.2, positive likelihood ratio = 3.53) than in 
GOLD grade III and IV (sensitivity = 76.1%, specificity = 
75.8%, negative likelihood ratio = 0.26, positive likeli-
hood ratio = 3.15).
 Discussion 
 We report that serum VIP is significantly higher at ex-
acerbation as compared to stable state COPD, suggesting 
its diagnostic potential to identify COPD patients at ex-
acerbation.
 AE-COPD is a serious cause of increased morbidity, 
mortality and disease-related expenditures  [34] . A bio-
marker with the potential to diagnose AE-COPD would 
therefore be beneficial for COPD management. Several 
serum markers have been reported to be upregulated at 
AE-COPD, such as C-reactive protein  [4] , copeptin and 
procalcitonin  [35] , tumor necrosis factor-α and leptin 
 [36] , endothelin-1  [37] , fibrinogen  [38, 39] , IL-6  [40] , 
IL-8  [41] , eosinophil cationic protein, myeloperoxidase 
 [42] and soluble urokinase-type plasminogen activator 
receptor  [43] . However, there has been no report on the 
relationship of serum VIP and AE-COPD. Therefore, to 
our knowledge, this is the first study analyzing the serum 
VIP levels in COPD patients at stable disease and acute 
exacerbation.
 Experimental studies showed that VIP relaxes vascular 
and non-vascular smooth muscles through the activation 
of adenylate cyclase and cyclic adenosine-3 ′ ,5 ′ -mono-
phosphate (cAMP) production  [44] , and due to this func-
tion as a vasodilator and bronchodilator, VIP was sug-
gested as a therapeutic target as well as a biomarker for 
COPD, asthma and PAH  [27] . In this study we did not 
observe increased VIP serum levels in COPD patients 
with PAH and did not find a correlation of VIP serum 
levels with low oxygen saturation as suggested by animal 
studies and in vitro models  [45–47] . It is difficult to ex-
plain this discrepancy between studies in animal and hu-
man beings, as it may not necessarily be reproducible in 
COPD patients. In murine models, lung remodeling and 
airway hyperreactivity increased when VIP levels were 
low, suggesting a therapeutic effect of exogenous VIP  [26, 
48] . In human epithelial cell lines VIP protected against 
hypoxia-induced tissue damage and increased experi-
mental wound repair through cAMP-dependent regula-
tory signaling  [24, 25] . Regarding exacerbation caused by 
viral infection, VIP was protective in mice against cyto-
megalovirus-induced lung damage  [19] . In contrast to 
these animal models, data obtained from human samples 
0
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 Fig. 4. Comparison of serum VIP levels in fast-frozen versus rou-
tinely processed serum samples (n = 20). Bars represent mean ± 
SEM and p value was calculated by Wilcoxon test. 
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indicated that serum VIP increases under similar patho-
logic conditions, suggesting that VIP is distinctly regu-
lated and has different functions in humans. Therefore 
the translation of animal studies to human diseases might 
not be straightforward.
 In this study, we observed a strong correlation of in-
creased serum VIP with AE-COPD and therefore suggest 
serum VIP as a potential biomarker to diagnose exacerba-
tion of COPD. This finding was supported by the longi-
tudinal observation that serum VIP was increased at AE-
COPD compared to stable state.
 Relating increased serum VIP in acute exacerbation to 
the protein’s known biological functions, it remains un-
clear whether this is the cause or the result of exacerba-
tion. VIP mediates its functions through two G protein-
coupled receptors, the VIP-pituitary adenylate cyclase ac-
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 Fig. 5.  a ROC curve of VIP (n = 283). AUC and 95% CI: 0.849 
(0.799–0.899).  b ROC curve of VIP in paired samples (n = 30). 
AUC and 95% CI: 0.908 (0.838–0.978).  c ROC curve of VIP in 
paired samples after the exclusion of extreme VIP values (n = 24). 
AUC and 95% CI: 0.910 (0.830–0.989). 
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tivating peptide receptors, VPAC1 and VPAC2  [49] . In 
humans and murine models the increased expression of 
VPAC1 in the airways of chronic bronchitis smokers, in 
the alveolar macrophages of COPD patients and in aller-
gic asthma was reported  [50–52] . This increased expres-
sion of VIP receptors may indicate that the ligand is miss-
ing, that the ligand is not active or that the signaling of the 
receptors is not correctly mediated. Unfortunately, up to 
now none of the previous studies has determined circu-
lating VIP levels in these patients and examined their as-
sociation to clinical characteristics, thus the role of VIP in 
COPD remains unclear.
 Furthermore, our results confirm the short half-life of 
VIP  [53, 54] , as only the fast-frozen serum samples con-
tained measurable amounts of VIP, while all other serum 
samples (repeatedly thawed, 1×) had non-detectable or 
very low amounts of VIP, thus only fast-processed or 
freshly drawn blood samples can be used if VIP is consid-
ered as an indicator of COPD patients at exacerbation 
 [27, 53–55] .
 Our study has few limitations. It was performed in a 
single center in Switzerland and included a relatively 
small number of patients with paired samples at exacer-
bation and at stable state. However, the diagnostic perfor-
mance of VIP in the whole study population was robust 
and improved considerably when the analysis was re-
stricted to the cohort with paired samples. A further lim-
itation is the fact that, currently, there is no gold standard 
to diagnose exacerbation of COPD. Accordingly, the di-
agnostic performance of VIP was compared to the widely 
accepted clinical definition of exacerbation. It is unclear 
whether the diagnostic performance of VIP would be 
maintained in a population presenting with clinical 
symptoms caused by other entities, such as congestive 
heart failure, pulmonary embolism or pneumonia. Thus, 
further studies including patients with conditions mim-
icking AE-COPD and a cost-effectiveness study compar-
ing VIP (EUR 25) to other costly examinations poten-
tially required to exclude AE-COPD (for instance, D-di-
mer EUR 32, brain natriuretic peptide EUR 70, chest 
X-ray EUR 120, chest CT EUR 250 and echocardiography 
EUR 350) would be of interest. Study strengths include 
the complete characterization of patients and disease 
characteristics at stable state and exacerbation and the 
dedicated sample handling for this particular biomarker 
determination. The study also benefits from the distinct 
diagnostic performance of the biomarker and the clinical 
potential associated with the presented findings.
 Conclusions 
 We present data strongly suggesting that increased se-
rum VIP in COPD patients indicates acute exacerbation. 
Therefore we suggest that serum VIP levels  ≥ 88 pg/ml be 
used as an indicator of exacerbation in COPD patients.
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